La chaîne d'options affiche les données clés des options sur actions de Denali Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Denali Therapeutics..

Denali Therapeutics (NASDAQ:DNLI) Stock, Chaîne d'Options

DENALI THERAPEUTICS INC

Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

UBS analyst Thomas Wadewitz maintains C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) with a Buy and lowers the price target from $130 to $129.

News

Price Target

Analyst Ratings

CHRW

UBS Maintains Buy on C.H. Robinson Worldwide, Lowers Price Target to $129

Truist Securities analyst David Smith maintains State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) with a Buy and raises the price target from $112 to $122.

Truist Securities Maintains Buy on State Street, Raises Price Target to $122

WIIM

LCID

Lucid shares are trading higher after the company reported Q2 production of 3,863 vehicles and deliveries of 3,309.

Truist Securities analyst David Smith maintains Northern Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>) with a Hold and raises the price target from $116 to $126.

NTRS

Truist Securities Maintains Hold on Northern Trust, Raises Price Target to $126

UBS analyst Myles Allsop maintains Core Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNR#NYSE">CNR</a>) with a Buy and lowers the price target from $80 to $78.

UBS Maintains Buy on Core Natural Resources, Lowers Price Target to $78

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Wolfe Research analyst Bill Carcache downgraded the rating for The PNC Financial Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) from Outperform to Peer Perform. PNC Financial shares closed at $195.70 on Wednesday. <a href="https://www.benzinga.com/quote/PNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jones Trading analyst Justin Walsh downgraded the rating for Theratechnologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) from Buy to Hold. Theratechnologies shares closed at $2.36 on Wednesday. <a href="https://www.benzinga.com/quote/THTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Trevor Cranston downgraded Two Harbors Investment Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) from Market Outperform to Market Perform. Two Harbors Investment shares closed at $10.65 on Wednesday. <a href="https://www.benzinga.com/quote/TWO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Maxim Group analyst Tate Sullivan downgraded the rating for NV5 Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) from Buy to Hold. NV5 Global shares closed at $23.22 on Wednesday. <a href="https://www.benzinga.com/quote/NVEE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying PNC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/PNC/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094948/image-44-1024x595.png" alt="" class="wp-image-972162" style="width:509px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094948/image-44-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094948/image-44-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094948/image-44-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094948/image-44.png 1127w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Markets

Trading Ideas

NVEE

THTX

This PNC Financial Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

UBS analyst Joshua Chan maintains UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) with a Neutral and lowers the price target from $196 to $194.

UBS Maintains Neutral on UniFirst, Lowers Price Target to $194

Loop Capital analyst Jeffrey Stevenson maintains BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) with a Buy and lowers the price target from $21 to $20.

Loop Capital Maintains Buy on BrightView Hldgs, Lowers Price Target to $20

UBS analyst Peter Grom maintains Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Buy and raises the price target from $195 to $205.

UBS Maintains Buy on Constellation Brands, Raises Price Target to $205

Macro Economic Events

Econ #s

Economics

S&P Global Composite PMI For June 52.9 Vs 52.8 Est.

Macro Notification

General

S&P Global Services PMI For June 52.9 Vs 53.1 Est.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Keybanc analyst Tim Rezvan initiated coverage on Prairie Operating Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROP#NASDAQ">PROP</a>) with a Sector Weight rating. Prairie Operating shares closed at $3.44 on Wednesday. <a href="https://www.benzinga.com/quote/prop/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Robert Burns initiated coverage on Telix Pharmaceuticals Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) with a Buy rating and announced a price target of $23. Telix Pharmaceuticals shares closed at $16.42 on Wednesday. <a href="https://www.benzinga.com/quote/tlx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Janney Montgomery Scott analyst Sean Milligan initiated coverage on Primoris Services Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) with a Buy rating and announced a price target of $102. Primoris Services shares closed at $82.00 on Wednesday. <a href="https://www.benzinga.com/quote/prim/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst David Ridley-Lane initiated coverage on Ralliant Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAL#NYSE">RAL</a>) with an Underperform rating and announced a price target of $48. Ralliant shares closed at $45.77 on Wednesday. <a href="https://www.benzinga.com/quote/ral/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying PRIM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094158/image-43-1024x574.png" alt="" class="wp-image-972152" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094158/image-43-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094158/image-43-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094158/image-43-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094158/image-43.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

Initiation

PRIM

PROP

This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday

Citigroup analyst Ronald Josey maintains CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Neutral and lowers the price target from $40 to $37.

CARG

Citigroup Maintains Neutral on CarGurus, Lowers Price Target to $37

<a href="https://truthsocial.com/@realDonaldTrump/114789577865630441">https://truthsocial.com/@realDonaldTrump/114789577865630441</a>

Politics

President Trump Posts On Truth Social "Will be speaking to President Putin of Russia at 10:00 A.M. Thank you!"

- Data from longer-term follow-up of patients in ongoing clinical trials further demonstrate durability of the clinical benefits of CASGEVY&#xAE; -
- Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients around the world -
TORONTO, July 3, 2025 /CNW/ - <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4462066-1&amp;h=2284321717&amp;u=https%3A%2F%2Fwww.vrtx.ca%2F&amp;a=Vertex+Pharmaceuticals">Vertex Pharmaceuticals</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) recently announced positive longer-term data for PrCASGEVY&#xAE; (exagamglogene autotemcel) from global ongoing pivotal clinical trials in people&nbsp;with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the European Hematology Association (EHA) Congress,&nbsp;continue to demonstrate the durable clinical benefits of CASGEVY. The longest follow up in SCD patients now extends more than 5.5 years and in TDT patients more than 6 years, with a mean of 39.4 months and 43.5 months, respectively. CASGEVY is the first authorized CRISPR/Cas9 gene-edited therapy.

Biotech

VRTX

Vertex's CASGEVY Shows Over 5.5 Years Of Durable Benefit In Sickle Cell And Beta Thalassemia Trials Presented At The EHA Congress; Multiple Reimbursement Agreements Secured

Citigroup analyst Filippo Falorni maintains Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Neutral and raises the price target from $170 to $174.

Citigroup Maintains Neutral on Constellation Brands, Raises Price Target to $174

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Lynozyfic (linvoseltamab-gcpt) for adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">least four prior lines of therapy</a>.
Lynozyfic was granted accelerated approval based on response rate and durability of response in the LINKER-MM1 trial. Continued approval for this indication may be contingent upon verification and description of clinical <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46223573/lynozyfic-linvoseltamab-gcpt-receives-fda-accelerated-approval-for-treatment-of-relapsed-or-refrac" rel="noreferrer noopener">benefit in a confirmatory trial</a>.
Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45755748/johnson-johnson-highlights-multiple-blood-cancer-trial-data-at-asco-presentation" rel="noreferrer noopener">Johnson &amp; Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation</a>
The regimen includes hospitalization for safety during the step-up dosing period (one 24-hour period after the first step-up dose, and another 24 hours after the second step-up dose).
The FDA approval for linvoseltamab in R/R MM is based on the pivotal Phase 1/2 LINKER-MM1 trial. In this trial, patients (n=80) experienced a 70% objective response rate (ORR), with 45% achieving a complete response (CR) or better.
The median time to first response was 0.95 months. The median duration of response (DoR) was not reached. Among responders, the estimated DoR was 89% at 9 months and 72% at 12 months, with a median follow-up of 13 months.
The prescribing information for Lynozyfic includes a Boxed Warning for cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome, in addition to warnings and precautions for infections, neutropenia, hepatotoxicity, and embryo-fetal toxicity.
In other news for the company, and highlighting their broader portfolio of approved treatments, in June, the FDA approved Regeneron and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (dupilumab) for adult patients with bullous pemphigoid (BP), a rare, chronic <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/46028780/fda-approves-regeneronm-sanofi-treatment-for-rare-autoimmune-skin-disorder" rel="noreferrer noopener">autoimmune skin disorder</a>.
BP primarily affects elderly patients and is characterized by intense itch, painful blisters and lesions, and skin reddening. It can be chronic and relapsing with&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46019439/dupixent-dupilumab-approved-in-the-u-s-as-the-only-targeted-medicine-to-treat-patients-with-bullou" rel="noreferrer noopener">underlying type 2 inflammation</a>.
Price Action: REGN stock is trading higher by 0.24% to 549.06 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46242132/crwd-stock-could-soar-16-says-wedbushs-dan-ives-coming-in-very-strong-with-healthy-momentum" target="_blank" rel="noreferrer noopener">CRWD Stock Could Soar 16%, Says Wedbush&#8217;s Dan Ives: &#8216;Coming In Very Strong With Healthy Momentum&#8217;</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Large Cap

Health Care

REGN

Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Laura Martin upgraded the rating for Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) from Underperform to Hold. Meta shares closed at $713.57 on Wednesday. <a href="https://www.benzinga.com/quote/meta/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Bill Carcache upgraded the rating for Huntington Bancshares Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) from Peer Perform to Outperform. Huntington Bancshares shares closed at $17.40 on Wednesday. <a href="https://www.benzinga.com/quote/hban/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying META stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/meta/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="597" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03093313/image-42-1024x597.png" alt="" class="wp-image-972142" style="width:588px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03093313/image-42-1024x597.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03093313/image-42-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03093313/image-42-768x447.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03093313/image-42.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a></li>
</ul>
Photo via Shutterstock

Upgrades

HBAN

This Meta Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Thursday

BGLWW

Blue Gold Partners With TripleBolt Technology To Explore Possible Development Of Blockchain-Based Digital Asset Backed By Gold Futures

AGRO

Adecoagro And Tether Sign MoU To Explore Strategic Collaboration Focused On Bitcoin Mining

Press Releases

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of  LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Earnings

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

Comments

Denali Therapeutics

Denali Therapeutics (DNLI) Options

Denali Therapeutics (NASDAQ:DNLI) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL